Clinical trial
Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
NCT02435914 is registered in ClinicalTrials.gov with Allergan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
- Lead sponsor
- Allergan
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2015
- Completion date
- January 31, 2016
- Enrollment
- 236 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.